ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Critical care and emergency · Crit Care Med · 2026-05-08

In REMAP-CAP, ivermectin did not improve organ support-free days in hospitalised COVID-19 patients: median -1 vs -1 in 61 critically ill (OR 0.94) and 22 vs 22 in 89 noncritically ill (OR 1.04). Enrolment stopped for operational futility.

RCTn = 150
Hashmi et al. Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Infectious diseases · Lancet Microbe · 2025-11-20

Substudy (secondary analysis) of a cluster-randomised malaria trial in Mozambique, 1951 participants: ivermectin mass drug administration lowered scabies prevalence at 3 months vs albendazole (2.11% vs 13.71%; aOR 0.18), including in untreated children under 5.

Secondary analysisn = 1,951
Furnival-Adams et al. Direct and indirect protection against scabies through ivermectin mass drug administration designed for malaria in Mozambique: a substudy nested within a cluster-randomised, controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.